Published in J Virol on October 01, 2004
Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci (2006) 2.56
Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet (2007) 1.50
hnRNP A1 interacts with the 5' untranslated regions of enterovirus 71 and Sindbis virus RNA and is required for viral replication. J Virol (2009) 1.41
Host factors in enterovirus 71 replication. J Virol (2011) 1.19
A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2, and polypyrimidine tract binding protein. J Virol (2005) 1.16
Mechanisms regulating expression of the HPV 31 L1 and L2 capsid proteins and pseudovirion entry. Virol J (2007) 1.08
The alternative splicing factor hnRNP A1 is up-regulated during virus-infected epithelial cell differentiation and binds the human papillomavirus type 16 late regulatory element. Virus Res (2007) 1.07
Regulation of human papillomavirus gene expression by splicing and polyadenylation. Nat Rev Microbiol (2013) 1.04
Human papillomavirus type 16 E2 protein transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF. J Virol (2008) 1.02
HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation. EMBO J (2012) 1.00
A downstream polyadenylation element in human papillomavirus type 16 L2 encodes multiple GGG motifs and interacts with hnRNP H. J Virol (2005) 0.99
Productive Lifecycle of Human Papillomaviruses that Depends Upon Squamous Epithelial Differentiation. Front Microbiol (2012) 0.98
The E1circumflexE4 protein of human papillomavirus interacts with the serine-arginine-specific protein kinase SRPK1. J Virol (2007) 0.90
Multiple ASF/SF2 sites in the human papillomavirus type 16 (HPV-16) E4-coding region promote splicing to the most commonly used 3'-splice site on the HPV-16 genome. J Virol (2010) 0.89
Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit. Proc Natl Acad Sci U S A (2005) 0.84
Suppression of HPV-16 late L1 5'-splice site SD3632 by binding of hnRNP D proteins and hnRNP A2/B1 to upstream AUAGUA RNA motifs. Nucleic Acids Res (2013) 0.83
hnRNP A1 interacts with the genomic and subgenomic RNA promoters of Sindbis virus and is required for the synthesis of G and SG RNA. J Biomed Sci (2010) 0.81
The RNA stability regulator HuR regulates L1 protein expression in vivo in differentiating cervical epithelial cells. Virology (2008) 0.80
Eight nucleotide substitutions inhibit splicing to HPV-16 3'-splice site SA3358 and reduce the efficiency by which HPV-16 increases the life span of primary human keratinocytes. PLoS One (2013) 0.79
RNA Binding Proteins that Control Human Papillomavirus Gene Expression. Biomolecules (2015) 0.78
Control of human papillomavirus gene expression by alternative splicing. Virus Res (2016) 0.78
Heterogeneous Nuclear Ribonucleoprotein C Proteins Interact with the Human Papillomavirus Type 16 (HPV16) Early 3'-Untranslated Region and Alleviate Suppression of HPV16 Late L1 mRNA Splicing. J Biol Chem (2015) 0.77
Keratinocyte Differentiation-Dependent Human Papillomavirus Gene Regulation. Viruses (2017) 0.75
Splicing and Polyadenylation of Human Papillomavirus Type 16 mRNAs. Int J Mol Sci (2017) 0.75
Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes. Cancer Cell Int (2013) 0.75
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet (2002) 16.29
Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell (1992) 7.90
Interactions between small nuclear ribonucleoprotein particles in formation of spliceosomes. Cell (1987) 7.44
Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst (1995) 6.24
RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J (1994) 6.17
Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol (1990) 5.64
The HIV-1 Rev protein. Annu Rev Microbiol (1998) 4.78
Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol (1990) 3.42
Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol Cell (2001) 3.34
hnRNP A/B proteins are required for inhibition of HIV-1 pre-mRNA splicing. EMBO J (1999) 3.04
Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1. Mol Cell Biol (1995) 2.55
In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc Natl Acad Sci U S A (1996) 2.54
Sequences homologous to 5' splice sites are required for the inhibitory activity of papillomavirus late 3' untranslated regions. Mol Cell Biol (1994) 2.49
Modulation of exon skipping by high-affinity hnRNP A1-binding sites and by intron elements that repress splice site utilization. EMBO J (1999) 2.34
Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression. J Biomed Sci (2004) 2.11
Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol (2001) 2.02
A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability. J Virol (1991) 1.95
Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2. J Biol Chem (1998) 1.88
The tat/rev intron of human immunodeficiency virus type 1 is inefficiently spliced because of suboptimal signals in the 3' splice site. J Virol (1994) 1.87
Papillomaviruses in human cancers. Proc Assoc Am Physicians (2000) 1.84
Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b. J Virol (1997) 1.82
The biology of human papillomaviruses: from warts to cancer. Infect Agents Dis (1993) 1.78
The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element. EMBO J (2001) 1.70
Heterogeneous nuclear ribonucleoprotein A1 binds to the transcription-regulatory region of mouse hepatitis virus RNA. Proc Natl Acad Sci U S A (1997) 1.70
An element in the bovine papillomavirus late 3' untranslated region reduces polyadenylated cytoplasmic RNA levels. J Virol (1991) 1.68
Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol (2002) 1.66
Analysis of human papillomavirus type 16 late mRNA 3' processing signals in vitro and in vivo. J Virol (1990) 1.62
Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. J Virol (1997) 1.59
Human papillomavirus type 31b late gene expression is regulated through protein kinase C-mediated changes in RNA processing. J Virol (1995) 1.57
PSF acts through the human immunodeficiency virus type 1 mRNA instability elements to regulate virus expression. Mol Cell Biol (2003) 1.43
RNA splicing at human immunodeficiency virus type 1 3' splice site A2 is regulated by binding of hnRNP A/B proteins to an exonic splicing silencer element. J Virol (2001) 1.41
The Rev protein of human immunodeficiency virus type 1 counteracts the effect of an AU-rich negative element in the human papillomavirus type 1 late 3' untranslated region. J Virol (1995) 1.40
mRNA instability elements in the human papillomavirus type 16 L2 coding region. J Virol (1998) 1.39
A pyrimidine-rich exonic splicing suppressor binds multiple RNA splicing factors and inhibits spliceosome assembly. Proc Natl Acad Sci U S A (1998) 1.37
HuR, a protein implicated in oncogene and growth factor mRNA decay, binds to the 3' ends of hepatitis C virus RNA of both polarities. Virology (2000) 1.34
A Janus splicing regulatory element modulates HIV-1 tat and rev mRNA production by coordination of hnRNP A1 cooperative binding. J Mol Biol (2002) 1.30
The inhibitory activity of the AU-rich RNA element in the human papillomavirus type 1 late 3' untranslated region correlates with its affinity for the elav-like HuR protein. J Virol (1999) 1.21
The human papillomavirus type 16 negative regulatory RNA element interacts with three proteins that act at different posttranscriptional levels. Proc Natl Acad Sci U S A (2000) 1.15
A cellular 65-kDa protein recognizes the negative regulatory element of human papillomavirus late mRNA. Proc Natl Acad Sci U S A (1997) 1.10
Synergistic stimulation of HIV-1 rev-dependent export of unspliced mRNA to the cytoplasm by hnRNP A1. J Mol Biol (1999) 1.10
Optimization of a weak 3' splice site counteracts the function of a bovine papillomavirus type 1 exonic splicing suppressor in vitro and in vivo. J Virol (2000) 1.08
Activity of the human papillomavirus type 16 late negative regulatory element is partly due to four weak consensus 5' splice sites that bind a U1 snRNP-like complex. J Virol (2003) 1.05
Regulation of human papillomavirus late gene expression. Ups J Med Sci (2000) 1.05
AU-rich mRNA instability elements on human papillomavirus type 1 late mRNAs and c-fos mRNAs interact with the same cellular factors. Oncogene (1997) 1.05
Inhibition of translation by UAUUUAU and UAUUUUUAU motifs of the AU-rich RNA instability element in the HPV-1 late 3' untranslated region. J Biol Chem (2002) 1.04
The human papillomavirus type 31 late 3' untranslated region contains a complex bipartite negative regulatory element. J Virol (2002) 1.01
Mutational inactivation of two distinct negative RNA elements in the human papillomavirus type 16 L2 coding region induces production of high levels of L2 in human cells. J Virol (2003) 0.98
The human immunodeficiency virus type 1 Rev protein and the Rev-responsive element counteract the effect of an inhibitory 5' splice site in a 3' untranslated region. Mol Cell Biol (1995) 0.95
Heterogeneous nuclear ribonucleoprotein C binds exclusively to the functionally important UUUUU-motifs in the human papillomavirus type-1 AU-rich inhibitory element. Virus Res (2001) 0.93
Function of a bovine papillomavirus type 1 exonic splicing suppressor requires a suboptimal upstream 3' splice site. J Virol (1999) 0.91
HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. Virology (2004) 0.89
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood (2012) 2.27
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood (2006) 2.15
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood (2013) 1.65
High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol (2006) 1.57
The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood (2009) 1.53
Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica (2009) 1.48
Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol (2007) 1.32
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One (2013) 1.17
Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR. J Hypertens (2004) 1.17
A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2, and polypyrimidine tract binding protein. J Virol (2005) 1.16
Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy. Support Care Cancer (2003) 1.10
CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. Haematologica (2008) 1.05
Regulation of human papillomavirus gene expression by splicing and polyadenylation. Nat Rev Microbiol (2013) 1.04
Inhibition of translation by UAUUUAU and UAUUUUUAU motifs of the AU-rich RNA instability element in the HPV-1 late 3' untranslated region. J Biol Chem (2002) 1.04
Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood (2008) 1.02
HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation. EMBO J (2012) 1.00
Increased expression of cellular RNA-binding proteins in HPV-induced neoplasia and cervical cancer. J Med Virol (2009) 0.99
Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol (2005) 0.99
A downstream polyadenylation element in human papillomavirus type 16 L2 encodes multiple GGG motifs and interacts with hnRNP H. J Virol (2005) 0.99
Mutational inactivation of two distinct negative RNA elements in the human papillomavirus type 16 L2 coding region induces production of high levels of L2 in human cells. J Virol (2003) 0.98
NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood (2006) 0.94
Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica (2007) 0.94
CNS aspergillosis: recognition, diagnosis and management. CNS Drugs (2007) 0.93
Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam. Clin Infect Dis (2004) 0.90
HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. Virology (2004) 0.89
Multiple ASF/SF2 sites in the human papillomavirus type 16 (HPV-16) E4-coding region promote splicing to the most commonly used 3'-splice site on the HPV-16 genome. J Virol (2010) 0.89
Inhibition of splicing by serine-arginine rich protein 55 (SRp55) causes the appearance of partially spliced HIV-1 mRNAs in the cytoplasm. Virus Res (2011) 0.89
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica (2010) 0.89
Insertional polymorphisms of endogenous HERV-K113 and HERV-K115 retroviruses in breast cancer patients and age-matched controls. AIDS Res Hum Retroviruses (2004) 0.88
Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias. Br J Haematol (2003) 0.88
Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica (2009) 0.87
Identification of a 17-nucleotide splicing enhancer in HPV-16 L1 that counteracts the effect of multiple hnRNP A1-binding splicing silencers. Virology (2007) 0.86
The presence of inhibitory RNA elements in the late 3'-untranslated region is a conserved property of human papillomaviruses. Virus Res (2007) 0.86
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy (2013) 0.86
Common clonal T-cell origin in a patient with T-prolymphocytic leukaemia and associated cutaneous T-cell lymphomas. Br J Haematol (2003) 0.85
Serine/arginine-rich protein 30c activates human papillomavirus type 16 L1 mRNA expression via a bimodal mechanism. J Gen Virol (2011) 0.85
Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses (2011) 0.85
Hydrops lysosomalis generalisatus--an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol (2006) 0.84
Expression of interleukin 15 in primary adult acute lymphoblastic leukemia. Cancer (2010) 0.84
Serine- and arginine-rich proteins 55 and 75 (SRp55 and SRp75) induce production of HIV-1 vpr mRNA by inhibiting the 5'-splice site of exon 3. J Biol Chem (2010) 0.84
Skewed expression of natural-killer (NK)-associated antigens on lymphoproliferations of large granular lymphocytes (LGL). Hematol Oncol (2006) 0.84
Suppression of HPV-16 late L1 5'-splice site SD3632 by binding of hnRNP D proteins and hnRNP A2/B1 to upstream AUAGUA RNA motifs. Nucleic Acids Res (2013) 0.83
Chronic norovirus infection in renal transplant recipients. Nephrol Dial Transplant (2008) 0.83
Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. Ann Hematol (2013) 0.82
Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients. J Hematol Oncol (2014) 0.82
Adenovirus E4orf4 induces HPV-16 late L1 mRNA production. Virology (2008) 0.82
Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse. Exp Hematol Oncol (2012) 0.81
Inhibition of HPV-16 L1 expression from L1 cDNAs correlates with the presence of hnRNP A1 binding sites in the L1 coding region. Virus Genes (2007) 0.81
An intron 9 containing splice variant of PAX2. J Transl Med (2009) 0.81
No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms. Retrovirology (2007) 0.81
Development and validation of a novel reporter assay for human papillomavirus type 16 late gene expression. J Virol Methods (2012) 0.81
Endogenous filamentous fungal endophthalmitis--single-centre survey in patients with acute leukaemia or postallogeneic stem cell transplantation and review of the literature. Mycoses (2011) 0.81
Inefficient splicing of segment 7 and 8 mRNAs is an inherent property of influenza virus A/Brevig Mission/1918/1 (H1N1) that causes elevated expression of NS1 protein. Virology (2011) 0.80
Erroneous class switching and false VDJ recombination: molecular dissection of t(8;14)/MYC-IGH translocations in Burkitt-type lymphoblastic leukemia/B-cell lymphoma. Mol Oncol (2013) 0.79
Eight nucleotide substitutions inhibit splicing to HPV-16 3'-splice site SA3358 and reduce the efficiency by which HPV-16 increases the life span of primary human keratinocytes. PLoS One (2013) 0.79
Molecular analysis of the t(2;8)/MYC-IGK translocation in high-grade lymphoma/leukemia by long-distance inverse PCR. Genes Chromosomes Cancer (2011) 0.79
Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group. Haematologica (2014) 0.78
Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann Hematol (2009) 0.78
Involvement of the MLL gene in adult T-lymphoblastic leukemia. Genes Chromosomes Cancer (2012) 0.77
Intramedullary abscess in a patient with disseminated Scedosporium apiospermum infection. Br J Haematol (2003) 0.77
Positive and negative effects on translation of the hepatitis C virus 3' untranslated region. J Hum Virol (2002) 0.75
Cell lineage assignment of cytogenetic findings in acute lymphoblastic leukemia using combined immunomagnetic cell separation and chromosome preparation. Haematologica (2003) 0.75